Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Cspc Pharmaceutical Group Limited, commonly referred to as Cspc, is a leading player in the pharmaceutical preparation manufacturing industry, headquartered in Hong Kong. Established in 1997, the company has made significant strides in developing a diverse range of high-quality pharmaceutical products, including innovative prescription medications and over-the-counter solutions.
Cspc operates extensively across major regions, including Asia and Europe, and is recognised for its commitment to research and development, which has led to numerous breakthroughs in therapeutic areas such as oncology and cardiovascular health. With a strong market position, Cspc has garnered accolades for its advanced manufacturing capabilities and adherence to stringent quality standards, solidifying its reputation as a trusted name in the global pharmaceutical landscape.
0 vs industry average
Cspc Pharmaceutical’s score of 42 is higher than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the least carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
CSPC Pharmaceutical, a Pharmaceutical Preparation Manufacturing company headquartered in HK, reported Scope 1 emissions of 474,567,040 kg CO2e and Scope 2 emissions of 493,310,000 kg CO2e in 2024. The company did not disclose Scope 3 emissions for this period. In 2023, its Scope 1 emissions were 663,224,000 kg CO2e and Scope 2 emissions were 418,037,000 kg CO2e.
CSPC Pharmaceutical has set several near-term, intensity-based reduction targets. For Scope 1 greenhouse gas emissions per unit revenue, the company aims to achieve a 53% reduction between 2024 and 2026, a 56% reduction between 2027 and 2028, and a 60% reduction between 2029 and 2030, all against a 2017 baseline. Similarly, for Scope 2 greenhouse gas emissions per unit revenue, targets include a 53% reduction between 2024 and 2026 and a 56% reduction between 2027 and 2028, also against a 2017 baseline. The company also commits to improving its management system to minimise its carbon footprint from operational activities by referencing the Task Force on Climate-related Financial Disclosures (TCFD) suggestions for identifying climate-related risks and opportunities between 2023 and 2025.
2025
Near-zero scope 1 & 2
Target to achieve near-zero emissions for direct operations and purchased energy
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more